BioSpace News Archive

Osivax announced that it has received a global pneumonia and pandemic preparedness grant of over USD 1M from the Bill & Melinda Gates Foundation to support additional research and development of its lead, broad-spectrum influenza vaccine candidate, OVX836.

Allarity Therapeutics, Inc. announced updates to its ongoing phase 2 clinical programs evaluating IXEMPRA® and stenoparib as monotherapies.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced positive results from the company’s Phase 1 single ascending dose and multiple ascending dose clinical trial of VK2735.

WuXi Biologics (“WuXi Bio”) (2269.HK) congratulates its strategic partner Amicus Therapeutics (“Amicus”) (Nasdaq: FOLD) on receiving European Commission’s approval for Pombiliti™ (cipaglucosidase alfa), a long-term enzyme replacement therapy (ERT) used in combination with miglustat for adults with late-onset Pompe disease (LOPD).

Milestone Pharmaceuticals Inc. announced that it has entered into a $125 million strategic funding agreement with existing shareholder, RTW Investments, LP and certain of its affiliates.

Theseus Pharmaceuticals, Inc. today announced that the company will participate in the Cantor Future of Oncology Virtual Symposium, taking place April 3-5, 2023.

Athira Pharma, Inc. presented preclinical data highlighting the potential therapeutic benefits of fosgonimeton at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders.

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio announced the availability of the Lumipulse G NfL CSF and Lumipulse G NfL Blood assays for the fully automated random-access LUMIPULSE® G immunoassay systems.

Captor Therapeutics S.A. discloses the identity of the drug targets as well as associated supporting data, and provides an update on the progress in the research and development of its pipeline lead programs CT-01, CT-02 and CT-05.

Burning Rock Biotech Limited, a company focused on the application of next generation sequencing technology in the field of precision oncology, reported financial results for the three months and the year ended December 31, 2022.